A prominent New Zealand entrepreneur has warned that financial institutions needed to take a punt on the emerging sector or risk losing business to Australia. [ + ]

Sydney biotech Peptech is on the hunt for a new CEO. [ + ]

BresaGen has reassured investors its projects are not threatened by potential regulation of stem cell research in Australia. [ + ]

A million-dollar collaboration between nano-drug company Starpharma and diagnostics specialist PanBio Ltd has come unstuck. [ + ]

Cryosite, a Sydney-based biotechnology service company that stores frozen biological material, is going public. [ + ]

Bumper year, 2003 - it's the 50th anniversary of the Watson and Crick's now famous paper on the structure of the DNA molecule. [ + ]

Biota Holdings' much-hyped influenza drug, Relenza, failed to contribute revenue in an interim result that saw the company record a loss of $3.2 million. [ + ]

Europe risks being left behind in the biotechnology sector unless it finds a way to address public fears about genetically modified organisms, a top European Union official has warned.

Australian scientists have launched a second-generation probe described as the biggest advance in microscopy since the electron microscope.

The success of a bioinformatics conference in Hong Kong in January has led to the establishment of three similar conferences in the Asia-Pacific region. [ + ]

A new network for the medical device industry is gearing up for launch. [ + ]

Plant breeders are expected to benefit from a joint venture between a Melbourne genetics company and the Victorian Government. [ + ]

Changes to Australian patent laws from April 1 will make filing harder, but will also bring the country more into line with US and European patent laws. [ + ]

South Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest. [ + ]

Victoria's government has backed stem cell research despite its existing ban on embryonic cell studies. [ + ]